Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00864357 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00864357 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 40 participants.
The verdict
NCT00864357, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, Inc., Lot No. 010550) in healthy adult volunteers under non-fasting conditions.
Interventions
- DRUG Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
- DRUG COMBONOX® tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-10 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00864357
The ClinicalTrials.gov registry entry for NCT00864357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose is the first listed.
NCT00864357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00864357 about?
NCT00864357 is a clinical study titled "A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions". To compare the relative bioavailability of oxycodone HCl 5 mg / ibuprofen 400 mg tablets (Actavis Elizabeth LLC, Lot No. PI-1565) with that of COMBONOX® tablets (Forest Pharmaceuticals, Inc., Lot No. 010550) in healthy adult volunteers under non-fasting conditions.
What is the current status of trial NCT00864357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-10. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00864357?
The interventions under investigation include: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose (DRUG), COMBONOX® tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00864357?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.